Dose reduction in a paediatric X-ray department following optimization of radiographic technique

A survey of radiation doses to children from diagnostic radiography has been carried out in a dedicated paediatric X-ray room. Entrance surface dose (ESD) and dose-area product (DAP) per radiograph were simultaneously measured with thermoluminescent dosemeters (TLDs) and a DAP meter to provide mean dose values for separate age ranges. Results of ESD and DAP were lower than the mean values from other UK studies for all ages and radiographs, except for the infant pelvis AP radiograph. Comparison of ESD and radiographic technique with CEC quality criteria highlighted a need for reduction of dose to infants and implied an increase in tube filtration might overcome the limitations of the room's three-phase, 12-pulse generator, allowing higher tube potentials to be used on infants. Additional tube filtration of 3 mmA1 was installed following assessment of dose reduction and image quality with test objects and phantoms, and confirmation from the paediatric radiologist that clinical image quality was not-significantly altered. The tube potential was increased from 50 to 56 kVp for the infant pelvis AP radiograph. The resulting ESD and effective dose fell by 51% and 38%, respectively. The CEC quality criteria have proved useful as a benchmark against which technique in X-ray departments can be compared, and as such are a useful tool for optimizing radiographic technique and reducing patient dose.     

A study of chest radiography with mobile X-ray units

A survey of radiographic technique and estimated entrance surface dose has been carried out for 364 chest radiographs performed with mobile X-ray equipment in the Intensive Therapy Unit (ITU) and 30 wards at Aberdeen Royal Infirmary. Data for these two types of location were compared, as were those for two film/screen systems used on the wards. Image quality assessments were made on sets of radiographs for two patients. Entrance skin doses for chest radiographs performed in the ITU were 50% greater than on the wards with the same film/screen system. The main technique difference was the use of shorter focus-to-skin distances (FSDs) in ITU. Doses with the Kodak Insight system were 20% higher than those using Du Pont Quanta III in similar locations. No correlation was found between image quality and entrance surface dose (ESD). Results from the survey were used to recommend exposure factors for shorter FSDs. A follow-up study revealed a 35-45% reduction in ESD for Kodak Insight and a 20% reduction for Quanta III.     

Influence of dose reduction recommendations on changes in chest radiography techniques

A previous dosimetric study on chest radiography identified ways to reduce patient entrance surface dose (ESD). This present study was designed to monitor changes that had occurred in the use of applied potential and film-screen sensitivity, after a series of recommendations were issued. The study falls into two parts: (1) an assessment of the impact of the recommendations and (2) what factors were responsible for change. Where changes had occurred, exposure factors were collected for 30 patients per tube and the mean ESD was calculated for each tube. Intercomparison (r = 0.93, p < 0.001) was made between calculated and measured (TLDs) values of mean ESD for 10 X-ray units, to ensure that the calculated values provided accurate estimates of the new mean ESDs. 89% of units previously monitored for patient ESD now use average applied potentials greater than 90 kVp and 51% are using film-screen sensitivities of 400. The mean ESD has been reduced on average by 47%, from 0.15 mGy to 0.08 mGy. It has been estimated that the annual collective dose from diagnostic radiology procedures in 30 hospitals in the West Midlands has been reduced by a value in excess of 40 man Sv. Reasons for change could be attributed to some of the following factors: (a) a knowledge of dose levels in comparison with other centres; (b) personal contact with departments; (c) feedback in terms of results and dose savings and (d) positive encouragement to make changes.     

Patient doses in hysterosalpingography

The results of a survey of doses imparted on 41 patients undergoing hysterosalpingography is presented. Dosimetric evaluations were carried out by measuring both the dose-area product using a transmission ionization type chamber, and the entrance surface dose using thermoluminiscent dosimeters. As a result, a local reference dose value was obtained for this examination. Correlations between the dose-area product and the entrance surface dose data were analysed and compared in order to find the most appropriate dosimetric procedure. The median dose-area product obtained was 713 cGy cm2 (range 247 cGy cm2-1623 cGy cm2). Ovarian doses were also calculated, and a median value of 4.6 mGy was obtained for the whole examination. Effective doses were estimated with a median value of 3.1 mSv, and a range of 1.0 mSv-8.1 mSv.     

Patient and staff radiation dose in fluoroscopy-guided TIPS procedures and dose reduction, using dedicated fluoroscopy exposure settings

Fluoroscopy guided interventions, such as transjugular intrahepatic portosystemic shunt (TIPS) procedures, can results in relatively high radiation doses to patients and staff. The purpose of this study was to evaluate the possible benefit of dedicated fluoroscopy exposure factors in the reduction of doses. Doses to patients and staff were measured during fluoroscopy-guided TIPS procedures in two Dutch university hospitals. Patient doses were calculated from dose-area product (DAP) measurements, entrance beam dimensions and DAP conversion factors. Staff doses were measured outside lead aprons using electronic personal dosemeters. Average patient entrance skin dose (ESD) rate during fluoroscopy was 49 mGy min-1 (13 cases, average fluoroscopy duration 32 min) in one hospital, and 6 mGy min-1 (10 cases, average fluoroscopy duration 50 min) in the other. Estimated staff effective dose per procedure was 28 microSv average in the first hospital compared with 4 microSv average in the other. The use of dedicated fluoroscopy exposure factors, with a relatively high tube voltage and lower tube current resulted in a significant dose reduction for patient and staff in this type of radiological intervention.     

Radiology in the neonatal intensive care unit: dose reduction and image quality

This paper describes a prospective study of the diagnostic radiation doses received in a neonatal intensive care unit (NICU) for a representative radiological technique used at our institution for a number of years and a "low dose" technique similar to that recommended by the Commission of the European Communities (CEC). A 400 speed film-screen combination was used in both techniques. A total of 363 anteroposterior (AP) chest and abdominal films of 77 neonates were accrued. For each radiograph, the entrance skin dose (FSD), energy imparted (EI) and mean whole body dose were determined. For a neonatal AP chest, there was an 18% reduction in the mean ESD per radiograph from 20.0 muGy for the representative technique to 16.4 muGy for the low dose technique (p < 0.0005). The reduction in the mean EI per radiograph values for the two techniques from 7.9 muJ to 7.1 muJ (10%) was statistically significant at the p < 0.017 level, after compensating for the difference in mean field dimensions between the two patient cohorts. The mean whole body dose per radiograph reduction from 4.4 to 3.5 muGy (20%) was statistically significant at the p < 0.0028 level. It was determined that the ESD and EI could be fitted by an exponential function in the equivalent patient diameter, a single parameter indicative of neonate size. Absolute excess childhood cancer mortality risk per film was estimated using risk factors derived for fetal exposures. A "worst case" absolute excess mortality risk per chest radiograph was estimated to be 1.40 x 10(-7) for the conventional technique and was further reduced to 1.11 x 10(-7) for the low dose technique. A blind comparison of patient-matched film pairs for each technique was performed by three radiologists using criteria similar to those specified by the CEC. No statistically significant difference in clinical image quality was found between the two techniques.     

A study of patient radiation doses in interventional radiological procedures

Patient radiation doses received during interventional radiological procedures can be significant. To aid in the establishment of reference dose levels, a patient dose survey has been conducted of such procedures. A total of 288 non-coronary procedures (177 classified as diagnostic and 111 as therapeutic) were accrued into the study. For each procedure, the fluoroscopy screening time and the fluoroscopic and digital radiographic dose-area products were recorded in a computer database. For example, median dose-area product values (due to fluoroscopy and digital radiography combined) of 24.2, 27.9, 69.6 and 74.7 Gy cm2 were obtained for nephrostomy, biliary stent removal/insertion, cerebral angiography and percutaneous transhepatic cholangiography procedures. While the effective dose is not an accurate measure of patient risk, it is convenient for comparing the radiological risks associated with various procedures. Effective doses were estimated from the total dose-area products. The respective median estimated effective dose values for the four procedures noted above were 3.9, 4.5, 7.0 and 12.0 mSv. While an infrequently performed procedure at this institution (n = 4 during this survey), the transjugular intrahepatic portosystemic shunt (TIPS) procedure had the greatest median dose-area product and effective dose values: 347 Gy cm2 and 55.5 mSv, respectively. Excluding the extreme case of TIPS, it was found that among commonly-performed procedures, those that are categorized as therapeutic do not necessarily present a statistically significant greater radiation risk than those which are diagnostic. Comparisons between dose-area product values obtained from this study are made with data from other interventional radiology patient dose surveys and reasons for some differences noted are discussed.     

A comparison of doses and techniques between specialist and non-specialist centres in the diagnostic X-ray imaging of children

A dosimetric survey of 14 routine X-ray examinations in children was carried out between 1993 and 1995. Two children's hospitals and four general hospitals took part in the survey which involved the calculation and measurement of nearly 3000 doses. Entrance surface doses (ESD) were calculated from exposure factors for radiographic procedures, and dose-area products (DAP) were recorded for both radiographic and fluoroscopic procedures. Doses were in good agreement with earlier studies, but for some procedures were significantly lower than those reported from other European countries. The main dose influencing factors for radiographic procedures were found to be the speed of the film-screen system and the use of an antiscatter grid. For the main head/trunk examinations, specialist centres often delivered higher doses to the younger children as a result of widespread use of a grid. In fluoroscopy, where the main dose influencing factors were the use of a grid and the dose rate dependence of the image intensifier, the children's hospitals consistently delivered significantly lower doses. Both ESDs and DAPs were found to increase with patient age for the main head/trunk examinations, although in some cases (AP/PA chest) this relationship was weak. The dependence of dose on age necessitates the subdivision of the paediatric sample into a number of age categories. It is suggested that all authors use the same age groupings.     

A survey of radiation doses to patients in mammography

The results are given of a survey of skin doses received in mammography by a phantom breast containing a simulated spherical tumour. The survey covered the 18 centres in New Zealand where mammography was carried out in 1976. The techniques used included xeroradiography, non-screen film and film with a back screen. If the best parameters for each technique were chosen, the "tumour" could be readily seen. Unfortunately this was not often the case and in practice only xeroradiography produced mammograms where the tumour was clearly seen in both the cranio-caudal and medio-lateral views. No centre produced a mammogram of the highest quality with an entrance dose of less than 1 rad. Within each technique there was a very wide range of entrance doses for the same quality of mammogram. At two centres with large workloads, the entrance doses to 11 patients were measured and, in general, the skin doses received by the patients were within 25% of those measured with the Rando phantom.     

The extension of the range of NIM alanine/ESR dosimetric system to therapy level

The NIM alanine/ESR dosimetric system, which was designed for industrial radiation processing, has been improved to be suited for applications in therapy dose range. Two different procedures of dose intercomparisons between IAEA and NIM were carried out with the improved system in the range of 2.5 to 100 Gy. In the first procedure, a set of NIM alanine dosimeters were irradiated at IAEA dosimetric laboratory and part of dosimeters marked "for evaluated" were evaluated using the rest of those with "known dose" given by IAEA. Most of evaluated doses agreed with IAEA doses within 1%. In the second procedure, all above dosimeters were evaluated on the base of NIM dosimetry. The results indicated that the doses determined by NIM agreed with those given by IAEA within 3% on the average.     

Prevention of cyclophosphamide-induced micronucleus formation in mouse bone marrow by indole-3-carbinol

Indole-3-carbinol (I3C) is a glucobrassicin derivative isolated from cruciferous vegetables. In this study, the protective effect of 13C is reported against cyclophosphamide (CP)-induced micronuclei formation in mouse bone marrow cells. The three test doses, namely 500, 250 and 125 mg/kg body weight of 13C provided protection when given 48 hr prior to the single ip administration of cyclophosphamide (50 mg/kg). The efficacy of the test doses of 13C was also evaluated using a lower dose of CP (25 mg/kg body weight). A significant inhibition in micronuclei formation was noticed with 13C at 250 and 125 mg/kg body weight dose. 13C could not induce micronuclei formation at the test doses 500 and 250 mg/kg body weight. 13C, therefore seems to have a preventive potential against CP-induced micronuclei formation in Swiss mouse bone marrow cells.     

Computing patient doses of X-ray examinations using a patient size- and sex-adjustable phantom

Both the use of traditional fluoroscopy and the increasing use of modern digital techniques in radiology and interventional radiology demand the development of versatile computer programs for patient dose determinations. Long computing times restrict the use of Monte Carlo (MC) methods in dose monitoring applications where the radiological views change frequently. In the Organ Doses Calculation Software application (ODS-60), the phantom model is similar in principle to the Alderson-Rando (A-R) phantom, but its sex, size and shape is modified according to a particular patient. Organ and effective doses are computed online (in a few seconds) using a method similar to the traditional dose planning systems used in radiotherapy. In this paper, the new ODS-60 software is presented in detail and its capabilities are demonstrated. Software performance was determined by comparing the results with those from independent methods. In the case of a reference man-sized male, the effective dose was about 7% larger than the effective dose given in another publication. In the case of a reference woman-sized female, the disagreement with the other method was greater (33%). Anatomical differences between the phantom models (ODS-60 and MC) were found to be the main reasons for these findings. This paper shows the advantage of using a patient size- and sex-adaptable phantom for patient dose determinations; the conversion coefficient from entrance surface dose-to-effective dose ratio between male (170 cm, 85 kg) and a female (160 cm, 43 kg) varies in the range 1.5-2.     

Methotrexate in juvenile rheumatoid arthritis. Evidence of age dependent pharmacokinetics

Children with juvenile rheumatoid arthritis (JRA) have been reported to require higher doses (per kg body weight) of methotrexate (MTX) than adults with rheumatoid arthritis to control their disease. The purpose of the present study was to characterise the plasma pharmacokinetics of MTX and its major metabolite, 7-hydroxymethotrexate (7-OHMTX) in children, and to compare the results with those previously obtained in adults. Thirteen patients (age 5-16 y) with JRA (median disease duration 5.5 y) were studied after once weekly oral administration of MTX (median 0.21 mg.kg-1). The analytical method was sufficiently sensitive to permit determination of plasma and urinary concentrations of MTX and 7-OHMTX during the entire dose interval in most of the patients. The dose normalized area under the plasma concentration versus time-curve (AUC) of MTX increased with the age of the children and was lower than previously found in adults. The dose normalized AUC of 7-OHMTX was not dependent on age. No correlation was found between the AUCs of MTX and 7-OHMTX. The results suggest that the age-dependence of the pharmacokinetics of MTX might explain the observation that at least some children require higher doses of MTX than adults to obtain a sufficient therapeutic effect.     

Evidence for safety margins of lignocaine local anaesthetics for peri-oral use

The evidence for the safety margins of doses of lignocaine local anaesthetics for standard injections for oral and dental purposes has been reviewed. Trials of peri-oral dosages leading to toxicity in humans have not been reported. The overwhelming evidence from trials of the normal dose range used clinically points to a restriction of total doses much lower than the 25 ml (500 mg) as published for 2% lignocaine with 1:80,000 adrenaline for a healthy adult. The recommendations are: 1. In mixtures of two pharmacologically active drugs (dual formulations) for peri-oral injections, to base the safety limit of local anaesthetic on the circulating level of lignocaine, rather than the amount of adrenaline contained in the injected volume. 2. Thus the suggested usual upper limit for dosage for a healthy adult patient is four and a half 2 ml (or 2.2-ml) cartridges of lignocaine with adrenaline (180-198 mg lignocaine or 2.57-2.82 mg/kg) body weight, if carefully given. 3. For some medically compromised patients, minimal doses only of lignocaine and adrenaline (about one cartridge) should be used and especial caution is necessary in patients likely to react adversely to the exogenous adrenaline of the dual formulation. 4. For both children and adults, the dosages should broadly be related to body size and note taken of the total dose which accrues from topical use of other formulations of lignocaine, such as pastes or creams or sprays. The doses injected should be the minimum that allow the treatment to proceed. If necessary the doses are better given at a series of appointments rather than as a large volume on one single occasion.     

Kainate/AMPA receptors expressed on human fetal astrocytes in long-term culture

OBJECTIVES: To study pravastatin and lovastatin pharmacokinetic and pharmacodynamic effects and their interactions with cydosporine (INN, ciclosporin) in kidney transplant patients after single and multiple doses. SUBJECTS AND METHODS: The pharmacokinetic and pharmacodynamic effects of administration of 20 mg/day oral pravastatin and lovastatin for 28 days and their interactions with cyclosporine (2 to 6 mg/kg/day) were studied in a double-blind, double-dummy, randomized, parallel-group multicenter trial in 44 stable kidney graft recipients. RESULTS: The median area under the curve [AUC(0-24)] of pravastatin was 249 microg x hr/L (range, 104 to 1026 microg x hr/L) after a single dose (day 1) and 241 microg x hr/L (114 to 969 microg x hr/L) after multiple doses (day 28) and was fivefold higher than values reported in the absence of cyclosporine. The median AUC(0-24) of lovastatin was 243 microg x hr/L (105 to 858 microg x hr/L) on day 1 and 459 microg x hr/L (140 to 1508 microg x hr/L) on day 28. Besides a significant accumulation during the study period (p < 0.001), the lovastatin AUC(0-24) values were twentyfold higher than values reported without cyclosporine. Coadministration of pravastatin or lovastatin did not alter cyclosporine pharmacokinetics. In this study, 20 mg/day doses of both drugs resulted in a significant improvement of the lipid profile and were well tolerated. CONCLUSIONS: In contrast to lovastatin, pravastatin did not accumulate over the study period, which is probably one of the reasons rhabdomyolysis has been reported in lovastatin-treated but not pravastatin-treated transplant patients receiving cyclosporine immunosuppression.     

Effects of acipimox on haemorheology and plasma lipoproteins in patients with mixed hyperlipoproteinaemia

Dolasetron mesilate is a selective 5-HT3 receptor antagonist that prevents chemotherapy-induced and postoperative nausea and vomiting. For the majority of patients in intravenous dolasetron trials for chemotherapy-induced nausea and vomiting, dosing has been based on body weight (mg/kg). The approved weight-based dose is 1.8 mg/kg based on results of controlled clinical trials. However, trials of dolasetron evaluating oral doses for prevention of chemotherapy-induced emesis, and intravenous doses for prevention and treatment of postoperative emesis have used a fixed milligram dose. To identify an appropriate intravenous fixed milligram dose for the prevention of chemotherapy-induced nausea and vomiting, this analysis was performed to derive efficacy results for fixed milligram doses from pooled results obtained with dosing based on body weight. Intravenous dolasetron doses for 1,598 patients treated on a mg/kg basis (0.3, 0.6, 1.2, 1.8, 2.4, 3.0 and 5.0 mg/kg) in 14 clinical trials were converted to fixed milligram doses based on weight. Fixed-dose groups were established at doses of 50, 75, 100, 125, 150, and 200 mg. Doses less than or equal to the midpoint between two dose groups were included in the lower dose group. Pooled results showed that the 100 mg intravenous dolasetron dose group (who received actual doses of 88-112 mg) produced the highest rate (53%) of complete response (0 emetic episodes and no rescue medication in the 24-h period following initiation of chemotherapy).     

An analysis of age and body weight at first calving for Holsteins in the United States

In a national survey of US dairy producers, only 2.7 +/- 0.5% of Holstein dairy operations reported achieving recommended target ranges of age < or = 24 months and body weight (BW) > or = 550 kg at first calving. Allowing for wider target ranges, still only 14.6 +/- 1.3% of Holstein dairy operations reported achieving age < or = 25 months and BW > or = 544.3 kg at first calving. Ages of individual first-calf heifers observed at calving were heavily skewed toward older individuals. Dairy producers reported an average age at first calving that was 1.3 months lower than the mean and 1.0 months lower than median age of first-calf heifers' observed calving on the operations. Stepwise logistic regression was used to identify the herd characteristics associated with producers reporting first calvings within the wider age and BW target ranges for Holsteins. Rolling herd average milk production > or = 7711 kg/yr, using a computer for recordkeeping, and not tying preweaned heifers in a barn with cows, were associated with achieving the target BW and age at first calving.     

EEG and clinical studies of the development of alumina cream epileptic focus in split-brain cats

Alumina cream epileptic focus was established in the right sensorimotor cortex in 20 split-brain cats (partial or complete). EEG and behavioral observations were made in a period ranging from 24 to 836 days. Four types of EEG changes after alumina cream injection were differentiated. These types could be related to the direct effects of brain damage and to development of epilepsy. Spikes and sharp waves and paroxysmal discharges (focal and multifocal) were observed in about 60% of the cats. Clinical seizures developed in about the same percentage of the animals. These values are below those reported for cats with intact interhemispheric commissures. Diphenylhydantoin (DPH) was given orally in a daily dose of up to 15 mg/kg body weight in 9 animals with developed epileptic EEG activity. Five of them had epileptic seizures. DPH was introduced not earlier than 1.5 months after intracortical alumina cream injection. The plasma level of DPH varied between 7-20 mug/ml. This dose produced chronic symptoms of intoxication. Neither EEG changes nor clinical seizures were entirely controlled by this drug. Additional doses of Relanium (diazepam), and phenobarbital were necessary to stop generalized seizures or status epilepticus.     

Radiological assessment of a new bone densitometer--the Lunar EXPERT

Dual energy X-ray absorptiometry (DXA) is one of the most widely used techniques in the management of osteoporosis and other skeletal diseases. Although patient doses from DXA are generally low, it is still necessary to measure them to assess the risk of radiation injury. We report on a study to estimate the effective dose (ED) to patients and staff from a new DXA scanner--the Lunar EXPERT, and make a comparison with a similar study carried out on a Lunar DPX-L. The entrance surface doses were measured to be 895 microGy and 10.25 microGy for the EXPERT and DPX-L, respectively. The EXPERT maximum EDs were calculated to be 74.7 microSv and 44.9 microSv for the anteroposterior (AP) lumbar spine and the proximal femur, respectively. More than 50% reduction in ED could be achieved by using a smaller scanning width. The maximum EDs for the DPX-L were calculated to be 0.21 microSv and 0.15 microSv for the AP lumbar spine and the proximal femur, respectively. The scattered dose rates (ambient dose equivalent) were measured to be less than 2 and less than 1 microSv h-1 at 50 cm and 100 cm, respectively, for the DPX-L, and the equivalent values for the EXPERT were 240 and 64 microSv h-1. Although both the patient dose and scattered dose rates are quite low relative to other radiological examinations, good practice aimed at dose reduction should still be implemented. Whilst protection for the operator is not needed for the DPX-L system, it may be (depending on the size of the room) for the EXPERT system.     

Pharmacodynamics of insulin Lispro in 2 patients with type II diabetes mellitus

We studied the effects of the new rapid acting human insulin analogue (Lys(B28), Pro(B29) insulin), insulin Lispro (Lispro) on metabolic control and insulin receptor binding in type II diabetes mellitus. We investigated 2 patients: Patient 1 was obese, clearly insulin-resistant, injected high doses of insulin (3-4 IU/kg body weight), and had insufficient diabetes control. Patient 2 was of normal body weight, injected normal insulin doses (0.7-0.8 IU/kg body weight), and had good diabetes control. Patient 1 showed a considerable improvement of insulin binding after receiving Lispro (26,700 vs. 5,600 receptors/monocyte; Kd 560 vs. 1,500 pM). Concommitantly, a decrease of serum glucose and insulin dose was observed, reflecting a higher insulin sensitivity during Lispro treatment. In patient 2 injected with Lispro the time course of serum glucose, serum insulin, and insulin binding after an oral meal was comparable to values obtained in healthy controls. We conclude that the quick and pulsatile pharmacokinetic profile of the insulin analogue Lispro may improve glycemia, insulin receptor binding, and insulin resistance in type II diabetes.